文献速递消化系统肿瘤

胃癌腹膜转移患者抗PD-1免疫治疗疗效生物标志物的探索

[Exploration of biomarkers for the efficacy of anti-PD-1 immunotherapy in patients with gastric cancer peritoneal metastasis].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2025-01-01

回顾性收集56例胃癌腹膜转移患者,41例接受抗PD-1治疗、15例未接受,两组总生存相似(15.2 vs 15.9个月,P=0.600)。基线载脂蛋白A1≥0.86 g/L者中位总生存优于低于该阈值者(17.7 vs 12.3个月,P=0.006),多因素分析显示载脂蛋白A1≥0.86 g/L是独立预后保护因素(HR=0.35,95%CI 0.12~0.98,P=0.046)。

要点

  • 抗PD-1治疗组与未治疗组总生存相似(15.2 vs 15.9个月,P=0.600)。
  • 基线载脂蛋白A1≥0.86 g/L者中位总生存17.7个月,优于低于该阈值者的12.3个月(P=0.006)。
  • 载脂蛋白A1≥0.86 g/L是抗PD-1治疗后总生存的独立保护因素(HR=0.35,95%CI 0.12~0.98,P=0.046)。

核心结论

  • 本研究首次提出载脂蛋白A1可能是识别胃癌腹膜转移患者免疫治疗生存获益的重要预测因子。

研究设计与样本

  • 回顾性研究,收集2020年3月至2023年9月南京大学医学院附属鼓楼医院接受一线治疗的胃癌腹膜转移患者56例,其中接受抗PD-1抗体免疫治疗41例、未接受15例。

主要发现

  • 接受抗PD-1治疗与未接受治疗患者总生存相似(15.2 vs 15.9个月,P=0.600)。
  • 基线高密度脂蛋白≥0.97 mmol/L者(n=22)中位总生存15.2个月,优于基线高密度脂蛋白<0.97 mmol/L者(n=19)的13.5个月(P=0.018)。
  • 基线载脂蛋白A1≥0.86 g/L者(n=21)中位总生存17.7个月,优于基线载脂蛋白A1<0.86 g/L者(n=20)的12.3个月(P=0.006)。
  • 基线甲胎蛋白升高者(n=2)中位总生存5.7个月,低于基线甲胎蛋白正常者(n=37)的15.2个月(P=0.005)。
  • 基线高水平载脂蛋白A1与更好的免疫治疗疗效相关(P=0.017)。

关键数值与推荐

  • 多因素Cox回归显示载脂蛋白A1≥0.86 g/L是抗PD-1治疗后总生存的独立保护因素(HR=0.35,95%CI 0.12~0.98,P=0.046)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the prognosis of patients with gastric cancer peritoneal metastasis (PM) receiving programmed cell death-1 (PD-1) antibody therapy, and investigate the biomarkers that affect the prognosis of anti-PD-1 therapy. Methods: This restrospecific study collected the clinic-pathological data of 56 patients with peritoneal metastasis of gastric cancer who received first-line treatment in the Nanjing Drum Town Hospital from March 2020 to September 2023, among which 41 had received anti-PD-1 immunotherapy and 15 hadn't. The relationship between overall survival (OS) and anti-PD-1 immunotherapy was evaluated by Kaplan-Meier analysis. The relationship between baseline peripheral blood indicators and treatment response of patients with anti-PD-1 treatment was analyzed using unpaired t-test. Subsequently, the Cox proportional risk regression model was used to explore the clinical prognostic factors that may affect anti-PD-1 immunotherapy by univariate and multivariate analysis. The clinical prognostic factors included baseline data and baseline peripheral blood indexes such as anti-PD-1 treatment lines, Eastern Cooperative Oncology Group performance status (ECOG PS), combined positive score (CPS), expression of human epidermal growth factor receptor 2 (Her-2), EBER status, pathological types, other metastatic lesions, ascites content before immunotherapy, with or without abdominal drainage during anti-PD-1 treatment, blood lipid indicators, inflammatory indicators, and tumor indicators. Results: Kaplan-Meier survival statistics showed similar OS (15.9 vs. 15.2 months, P=0.600) in patients with anti-PD-1 therapy compared to those without anti-PD-1 therapy. Patients with baseline high-density lipoprotein (HDL) ≥0.97 mmol/L (n=22) demonstrated a significantly longer median OS compared to those with HDL<0.97 mmol/L (15.2 vs. 13.5 months; P=0.018). Similarly, the cohort with apolipoprotein A1 (ApoA1) levels ≥0.86 g/L (n=21) showed superior survival outcomes, with a median OS of 17.7 months versus 12.3 months in the ApoA1<0.86 g/L group (n=20; P=0.006). In contrast, elevated baseline alpha-fetoprotein (AFP) levels (n=2) were associated with markedly reduced survival (median OS: 5.7 vs. 15.2 months in normal AFP group, n=37; P=0.005). Notably, elevated pretreatment ApoA1 levels correlated with enhanced immunotherapy response (P=0.017). Multivariate Cox regression analysis revealed that ApoA1 deficiency (≥0.86 g/L) independently predicted better OS following PD-1 antibody therapy (HR=0.35, 95% CI: 0.12-0.98, P=0.046) in gastric cancer patients with PM. Conclusions: In our study, it is first proposed that ApoA1 could be a significant predictor of the survival advantages of immunotherapy in gastric cancer patients with PM. 目的: 探讨胃癌腹膜转移患者接受程序性死亡受体1(PD-1)抗体治疗的预后情况,分析影响抗PD-1治疗预后的生物标志物。 方法: 回顾性收集2020年3月至2023年9月南京大学医学院附属鼓楼医院接受一线治疗的胃癌腹膜转移患者的临床病理资料(56例),其中接受PD-1抗体免疫治疗41例,未接受PD-1抗体免疫治疗15例。使用Kaplan-Meier生存分析评估患者总生存时间(OS)与PD-1抗体免疫治疗的关系,采用独立样本t检验分析基线外周血指标与患者抗PD-1治疗疗效的关系,影响因素分析采用Cox比例风险回归模型。 结果: Kaplan-Meier生存分析结果显示,接受PD-1抗体治疗和未接受治疗患者有相似的OS(分别为15.2和15.9个月,P=0.600)。基线高密度脂蛋白(HDL)≥0.97 mmol/L的患者(n=22)中位OS为15.2个月,优于基线HDL<0.97 mmol/L的患者(n=19;13.5个月,P=0.018)。基线载脂蛋白A1(ApoA1)≥0.86 g/L 的患者(n=21)中位OS为17.7个月,优于基线ApoA1<0.86 g/L的患者(n=20;12.3个月,P=0.006)。基线甲胎蛋白(AFP)升高的患者(n=2)中位OS为5.7个月,显著低于基线AFP正常的患者(n=37;15.2个月,P=0.005)。基线高水平ApoA1与更好的免疫治疗疗效相关(P=0.017)。多因素分析显示,ApoA1≥0.86 g/L(HR=0.35,95% CI:0.12~0.98,P=0.046)是影响胃癌腹膜转移患者PD-1抗体治疗后OS的独立预后保护因素。 结论: ApoA1可能是识别胃癌腹膜转移患者免疫治疗生存获益的重要预测因子。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wei YT, Wang Y, Yang J, et al. [Exploration of biomarkers for the efficacy of anti-PD-1 immunotherapy in patients with gastric cancer peritoneal metastasis]. Zhonghua Zhong Liu Za Zhi. 2025. PMID: 40069088. doi:10.3760/cma.j.cn112152-20240826-00368

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。